JP2009536221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536221A5 JP2009536221A5 JP2009510118A JP2009510118A JP2009536221A5 JP 2009536221 A5 JP2009536221 A5 JP 2009536221A5 JP 2009510118 A JP2009510118 A JP 2009510118A JP 2009510118 A JP2009510118 A JP 2009510118A JP 2009536221 A5 JP2009536221 A5 JP 2009536221A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tetrazole
- conr
- phenyl
- och
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79800106P | 2006-05-05 | 2006-05-05 | |
| US60/798,001 | 2006-05-05 | ||
| PCT/US2007/068342 WO2007131219A2 (en) | 2006-05-05 | 2007-05-07 | Cannabinoid receptor antagonists/inverse agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536221A JP2009536221A (ja) | 2009-10-08 |
| JP2009536221A5 true JP2009536221A5 (enExample) | 2010-06-24 |
| JP5561720B2 JP5561720B2 (ja) | 2014-07-30 |
Family
ID=38668620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510118A Expired - Fee Related JP5561720B2 (ja) | 2006-05-05 | 2007-05-07 | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト／インバ−スアゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7482470B2 (enExample) |
| EP (1) | EP2023920B1 (enExample) |
| JP (1) | JP5561720B2 (enExample) |
| CN (1) | CN101484161A (enExample) |
| AU (1) | AU2007247878B2 (enExample) |
| CA (1) | CA2651385C (enExample) |
| ES (1) | ES2389569T3 (enExample) |
| IL (1) | IL195071A (enExample) |
| WO (1) | WO2007131219A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| WO2009085198A2 (en) * | 2007-12-20 | 2009-07-09 | Indigene Pharmaceuticals, Inc. | Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011044370A1 (en) | 2009-10-07 | 2011-04-14 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| JP5946192B2 (ja) * | 2010-11-18 | 2016-07-05 | ジェンリン ディスカバリーＪｅｎｒｉｎ Ｄｉｓｃｏｖｅｒｙ | 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬 |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8680131B2 (en) | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
| US9765031B2 (en) | 2012-11-13 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| AU2015255765A1 (en) * | 2014-05-09 | 2016-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| KR20210152312A (ko) | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2023089612A1 (en) | 2021-11-19 | 2023-05-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peripheral cb1 receptor antagonists for treatment of lower urinary tract symptoms (luts) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0882029B1 (en) | 1996-02-02 | 2003-04-02 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
| CA2244831A1 (en) | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
| WO1997028115A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
| EP0904079B1 (en) | 1996-02-02 | 2004-03-24 | Merck & Co., Inc. | Antidiabetic agents |
| HUP0204519A3 (en) * | 2000-03-23 | 2003-07-28 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations |
| HUP0402113A3 (en) * | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
| KR100903760B1 (ko) * | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
-
2007
- 2007-05-07 ES ES07761946T patent/ES2389569T3/es active Active
- 2007-05-07 WO PCT/US2007/068342 patent/WO2007131219A2/en not_active Ceased
- 2007-05-07 AU AU2007247878A patent/AU2007247878B2/en not_active Ceased
- 2007-05-07 CN CNA2007800249328A patent/CN101484161A/zh active Pending
- 2007-05-07 EP EP07761946A patent/EP2023920B1/en not_active Not-in-force
- 2007-05-07 JP JP2009510118A patent/JP5561720B2/ja not_active Expired - Fee Related
- 2007-05-07 CA CA2651385A patent/CA2651385C/en active Active
- 2007-05-07 US US11/745,162 patent/US7482470B2/en active Active
-
2008
- 2008-10-14 US US12/250,654 patent/US7666889B2/en active Active
- 2008-11-03 IL IL195071A patent/IL195071A/en active IP Right Grant
-
2010
- 2010-01-12 US US12/685,695 patent/US8088809B2/en not_active Expired - Fee Related
-
2011
- 2011-12-23 US US13/336,733 patent/US20130005784A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536221A5 (enExample) | ||
| JP2009529540A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2006151984A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2007534702A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2008510770A5 (enExample) | ||
| JP2010515731A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2012515776A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2011522789A5 (enExample) | ||
| JP2010503698A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| CA2569850A1 (en) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer | |
| JP2012006912A5 (ja) | トリアゾール誘導体 | |
| JP2014509612A5 (enExample) | ||
| JP2006520397A5 (enExample) | ||
| JP2019529419A5 (enExample) | ||
| JP2015524019A5 (enExample) | ||
| JP2020128426A5 (enExample) | ||
| JP2009539943A5 (enExample) |